We further validated the efficacy of combining romidepsin with mTOR inhibitors in the uveal melanoma cell lines by examining the downstream mTOR pathway target S6, as well as PARP and caspase-3 cleavage after treatment with the various mTOR inhibitors in the absence or presence of romidepsin. This evidence concerns the gene MTOR and uveal melanoma.